AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial

Published by

By Julie Steenhuysen CHICAGO (Reuters) – AstraZeneca Plc’s COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65 and older, according to long-awaited results of the company’s U.S. clinical trial published on Wednesday. Overall efficacy of 74% was lower than the interim 79% figure reported by the British drugmaker in March, a result AstraZeneca revised days later to 76% after a rare public rebuke from health officials that the figure was based on “outdated information.” The data looked at more than 26,000 volunteers in t…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *